Corautus
Genetics
About Corautus Genetics Corautus Genetics is a biotechnology
company dedicated to the clinical development of new therapies for the treatment
of patients with serious diseases, including severe cardiovascular and peripheral
THE a vascular growth factor gene VEGF-2. GENASIS ("Genetic Angiogenic Stimulation Investigational
Study") trial to evaluate the safety and efficacy of Vascular Endothelial Growth
Factor-2 (VEGF-2) for the treatment of patients with Class III and IV angina who
are not candidates for current revascularization techniques and for whom surgery
is not advisable.
More
About Corautus